Fortune July 6, 2025
Beatrice Nolan

  • Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately.

Alphabet’s secretive drug discovery arm, Isomorphic Labs, is getting ready to start testing its AI-designed drugs in humans, Colin Murdoch, Isomorphic Labs president and Google DeepMind’s chief business officer, told Fortune.

“There are people sitting in our office in King’s Cross, London, working, and collaborating with AI to design drugs for cancer,” Murdoch said during an interview in Paris. “That’s happening right now.”

After years in development, Murdoch says human clinical trials...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Technology, Trends
Related Articles:
AI-enabled clinical data abstraction: a nurse’s perspective
Contextual AI launches Agent Composer to turn enterprise RAG into production-ready AI agents
OpenAI’s latest product lets you vibe code science
WISeR in 2026: Legal, Compliance, and AI Challenges That Could Reshape Prior Authorization for Skin Substitutes
Dario Amodei warns AI may cause ‘unusually painful’ disruption to jobs

Share Article